Quantum chemistry meets cancer treatment QDX and Prelude Therapeutics are developing drugs that selectively target the JAK2 V617F mutation, offering hope for patients with myeloproliferative neoplasms.

https://www.drugdiscoverynews.com/quantum-chemistry-meets-cancer-treatment-16860?utm_campaign=DDN_Newsletter_Science%20Spotlight&utm_medium=email&_hsenc=p2ANqtz--aShExhfm9TxVNgS0O642JbpkphvpNjTZSMonCumCBAkwDgRUgfeyjVIVzXPNfHtBLU7aNkZGbJFntPBh3P_iQMZCwKg&_hsmi=393164912&utm_content=393164912&utm_source=hs_email